MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Hospital Clínico San Carlos de Madrid](/img/noimage_org.png)
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (106)
2024
-
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559
2023
-
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
Frontiers in Oncology, Vol. 12
-
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Cancers, Vol. 14, Núm. 3
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
-
Treatment with Adjuvant Abemaciclib Plus Endocrine Therapy in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
JAMA Oncology, Vol. 8, Núm. 8, pp. 1190-1194
-
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study
European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome
Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 2, pp. 462-470
-
Trajectories of alcohol consumption during life and the risk of developing breast cancer
British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176
2020
-
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Future Oncology, Vol. 16, Núm. 33, pp. 2763-2778
-
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
Oncologist, Vol. 25, Núm. 9, pp. e1339-e1345
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Scientific Reports, Vol. 10, Núm. 1
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2019
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1